Indian Journal of Clinical Biochemistry

, Volume 28, Issue 3, pp 265–271

Urinary Tumor Markers Could Predict Survival in Bladder Carcinoma

  • Ragaa H. M. Salama
  • Tahia H. Selem
  • Mohammed El-Gammal
  • Abd-elmoneim A. Elhagagy
  • Sally M. Bakar
Original Article


The early diagnosis of bladder cancer is important for effective treatment of the disease. This study aimed to evaluate the nuclear matrix protein 22 (NMP 22), soluble epithelial cadherin (E-cadherin), cathepthin-D and total protein with clinico-pathological features of bladder cancer, and to determine the relation between each marker and tumor progression after treatment. The study includes 65 patients with bladder cancer, 14 benign urinary diseases and 11 healthy volunteers. Patients were categorized according to bilharzial infestation, T stage, tumor grade, size and the presence of lymph node metastasis. Forty patients were followed for disease progression after surgery. There was a significant increase of NMP22, E-cadherin, cathepthin-D and total protein detected in cancer group compared to healthy and benign groups. It was found that NMP 22 and E-cadherin had highest sensitivity (84.4, 76.9 %, respectively) while, total ddedprotein showed highest specificity (77.4 %). Tumor size correlated with urinary NMP22 (r = 0.3, p = 0.02), although, E-cadherin, cathepsin-D and total protein correlated with tumor size (r = 0.3, 0.28, 0.2; p = 0.01, p = 0.01, 0.04, respectively) and lymph node metastasis (r = 0.32, 0.34, 0.2; p = 0.003, 0.005, 0.04, respectively). Elevated pretreatment urinary NMP22, E-cadherin and total protein levels was associated significantly with bladder cancer recurrence (p = 0.02, 0.001, 0.005, respectively). In conclusion, determination of urinary NMP22, E-cadherin and total protein in bladder cancer patients or persons at risk of developing bladder cancer will help in early detection of the disease and prediction of recurrence. The use of a combination of tumor markers is markedly useful than the assessment of single one.


NMP22 Cadherin Cathepsin D Total protein Bladder carcinoma 


  1. 1.
    el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. Semin Oncol. 2001;28:174–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003;170:2244–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Sjakste N, Sjakste T, Vikmanis U. Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis. Exp Oncol. 2004;26:170–8.PubMedGoogle Scholar
  4. 4.
    Bredel M, Pollack IF, Hamilton RL, Birner P, Hainfellner JA, Zentner J. DNA topoisomerase IIalpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas. Int J Cancer. 2002;99:817–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Chang HW, Chow V, Lam KY, Wei WI, Yuen A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer. 2002;94(2):386–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184(2):423–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene. 2002;21:5951–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Hardwicke J. Proteinuria. Sci Basis Med Annu Rev. 1970; 1:211–29.Google Scholar
  9. 9.
    Zhau HY, Babaian RJ, Hong SJ. A new 180 kDa urine protein marker associated with bladder cancer. J Urol. 1990;144:47–52.PubMedGoogle Scholar
  10. 10.
    Kuhn SH, de Kock MA. A preliminary study of elevated alkaline phosphatase and cathepsin in bronchial aspirates of patients with lung cancer and bronchitis. Chest. 1975;68:326–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283–98.PubMedCrossRefGoogle Scholar
  12. 12.
    Reinert T. Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol. 2012;2012:503271.Google Scholar
  13. 13.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 2002;168:465–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Gödekmerdan A, Yahşi S, Semerciöz A, Ilhan F, Akpolat N, Yekeler H. Determination of nuclear matrix protein 22 levels in cystitis, urothelial dysplasia and urothelial carcinoma. Turk J Med Sci. 2006;36:93–6.Google Scholar
  15. 15.
    Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol. 2001;165:1462–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder. Cancer Detect Prev. 2000;24:364–8.PubMedGoogle Scholar
  17. 17.
    Casella R, Huber P, Blochlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol. 2000;164:1926–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, et al. Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer-NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 study group. Gan To Kagaku Ryoho. 1997;24:829–36.PubMedGoogle Scholar
  19. 19.
    O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves CF, Yoon HS, Hinder V, Masters J, Kennedy-Smith A, Beaven T, Guilford PJ. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012 [Epub ahead of print].Google Scholar
  20. 20.
    Sumi S, Arai K, Kitahara S, Yoshida KI. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta. 2000;296:111–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int. 1999;84:706–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Horstmann M, Todenhöfer T, Hennenlotter J, Aufderklamm S, Mischinger J, Kuehs U, Gakis G, Stenzl A, Schwentner C. Influence of age on false positive rates of urine-based tumor markers. World J Urol. 2012. [Epub ahead of print].Google Scholar
  23. 23.
    Hutterer GC, Karakiewicz PI, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, et al. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int. 2008;101:561–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003;170:2248–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int. 2008;81:320–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Staack A, Tolic D, Kristiansen G, Schnorr D, Loening SA, Jung K. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology. 2004;63:1089–94.PubMedCrossRefGoogle Scholar
  27. 27.
    Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res. 2005;65:2993–5.PubMedGoogle Scholar
  28. 28.
    Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol. 1996;155:2113–9.PubMedCrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2012

Authors and Affiliations

  • Ragaa H. M. Salama
    • 1
    • 3
  • Tahia H. Selem
    • 1
  • Mohammed El-Gammal
    • 2
  • Abd-elmoneim A. Elhagagy
    • 2
  • Sally M. Bakar
    • 1
  1. 1.Biochemistry DepartmentFaculty of Medicine, Assiut UniversityAssiutEgypt
  2. 2.Urology DepartmentFaculty of Medicine, Assiut UniversityAssiutEgypt
  3. 3.Department of Medical BiochemistryFaculty of Medicine, Assiut UniversityAssiutEgypt

Personalised recommendations